Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment
The appropriate sequencing of agents with strong immune system effects has become increasingly important. Transitions require careful balance between safety and protection against relapse. The cases presented herein highlight that rebound events after ceasing fingolimod treatment may happen even wit...
Gespeichert in:
| Veröffentlicht in: | JAMA neurology Jg. 73; H. 7; S. 790 - 794 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.07.2016
|
| Schlagworte: | |
| ISSN: | 2168-6157 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | The appropriate sequencing of agents with strong immune system effects has become increasingly important. Transitions require careful balance between safety and protection against relapse. The cases presented herein highlight that rebound events after ceasing fingolimod treatment may happen even with short washout periods (4 weeks) and may perpetuate despite steroid treatment or the immediate use of fast-acting immune therapies, such as rituximab.
To describe rebound syndrome in patients with multiple sclerosis (MS) after cessation of fingolimod treatment.
Clinical and demographic data were extracted from electronic medical records from the University of California, San Francisco, Multiple Sclerosis Center from January 2014 to December 2015. Magnetic resonance images were reviewed by MS neurologists (J.S.G., E.W., B.N., and E.C.H.). Rebound syndrome was defined as new severe neurological symptoms after ceasing fingolimod treatment, with the development of multiple new or enhancing lesions exceeding baseline activity. We reviewed the PubMed database from January 2010 to December 2015 for similar cases of severe disease reactivation after ceasing fingolimod treatment using search terms fingolimod and either rebound or reactivation. Participants were included if they stopped receiving fingolimod between January 2014 and December 2015. Five patients were identified who experienced rebound after ceasing fingolimod treatment.
Each patient received treatment with oral fingolimod for various durations.
Occurrence of rebound after ceasing fingolimod treatment.
The mean (SD) age of the 5 female patients presented in this case series was 35.2 (6.4) years. Of the 46 patients that stopped fingolimod treatment within the 2-year period, 5 (10.9%) experienced severe relapse 4 to 16 weeks after ceasing fingolimod treatment. Despite varying prior severity of relapsing-remitting course, all participants experienced unexpectedly severe clinical relapses accompanied by drastic increases in new or enhancing lesions seen on magnetic resonance imaging evidenced by a median (range) increase of 9 (0->30) new gadolinium-enhancing lesions and a median (range) of 9 (0->30) new T2 lesions. New lesion development persisted for 3 to 6 months despite treatment with corticosteroids (n = 3) and initiation of B-cell depleting therapy (n = 2). In addition, 11 patients were identified through literature review reported as having severe relapses consistent with a rebound syndrome and similar features to our 5 cases.
These cases provide evidence for a fingolimod rebound syndrome at a clinically relevant frequency, highlighting the need to determine the best methods for sequencing or discontinuing MS therapies. A large prospective registry or population-based study would be helpful to confirm this rebound phenomenon and to determine contributing factors, including immune biomarkers, that increase risk for this syndrome. |
|---|---|
| AbstractList | The appropriate sequencing of agents with strong immune system effects has become increasingly important. Transitions require careful balance between safety and protection against relapse. The cases presented herein highlight that rebound events after ceasing fingolimod treatment may happen even with short washout periods (4 weeks) and may perpetuate despite steroid treatment or the immediate use of fast-acting immune therapies, such as rituximab.
To describe rebound syndrome in patients with multiple sclerosis (MS) after cessation of fingolimod treatment.
Clinical and demographic data were extracted from electronic medical records from the University of California, San Francisco, Multiple Sclerosis Center from January 2014 to December 2015. Magnetic resonance images were reviewed by MS neurologists (J.S.G., E.W., B.N., and E.C.H.). Rebound syndrome was defined as new severe neurological symptoms after ceasing fingolimod treatment, with the development of multiple new or enhancing lesions exceeding baseline activity. We reviewed the PubMed database from January 2010 to December 2015 for similar cases of severe disease reactivation after ceasing fingolimod treatment using search terms fingolimod and either rebound or reactivation. Participants were included if they stopped receiving fingolimod between January 2014 and December 2015. Five patients were identified who experienced rebound after ceasing fingolimod treatment.
Each patient received treatment with oral fingolimod for various durations.
Occurrence of rebound after ceasing fingolimod treatment.
The mean (SD) age of the 5 female patients presented in this case series was 35.2 (6.4) years. Of the 46 patients that stopped fingolimod treatment within the 2-year period, 5 (10.9%) experienced severe relapse 4 to 16 weeks after ceasing fingolimod treatment. Despite varying prior severity of relapsing-remitting course, all participants experienced unexpectedly severe clinical relapses accompanied by drastic increases in new or enhancing lesions seen on magnetic resonance imaging evidenced by a median (range) increase of 9 (0->30) new gadolinium-enhancing lesions and a median (range) of 9 (0->30) new T2 lesions. New lesion development persisted for 3 to 6 months despite treatment with corticosteroids (n = 3) and initiation of B-cell depleting therapy (n = 2). In addition, 11 patients were identified through literature review reported as having severe relapses consistent with a rebound syndrome and similar features to our 5 cases.
These cases provide evidence for a fingolimod rebound syndrome at a clinically relevant frequency, highlighting the need to determine the best methods for sequencing or discontinuing MS therapies. A large prospective registry or population-based study would be helpful to confirm this rebound phenomenon and to determine contributing factors, including immune biomarkers, that increase risk for this syndrome. IMPORTANCEThe appropriate sequencing of agents with strong immune system effects has become increasingly important. Transitions require careful balance between safety and protection against relapse. The cases presented herein highlight that rebound events after ceasing fingolimod treatment may happen even with short washout periods (4 weeks) and may perpetuate despite steroid treatment or the immediate use of fast-acting immune therapies, such as rituximab.OBJECTIVETo describe rebound syndrome in patients with multiple sclerosis (MS) after cessation of fingolimod treatment.DESIGN, SETTING, AND PARTICIPANTSClinical and demographic data were extracted from electronic medical records from the University of California, San Francisco, Multiple Sclerosis Center from January 2014 to December 2015. Magnetic resonance images were reviewed by MS neurologists (J.S.G., E.W., B.N., and E.C.H.). Rebound syndrome was defined as new severe neurological symptoms after ceasing fingolimod treatment, with the development of multiple new or enhancing lesions exceeding baseline activity. We reviewed the PubMed database from January 2010 to December 2015 for similar cases of severe disease reactivation after ceasing fingolimod treatment using search terms fingolimod and either rebound or reactivation. Participants were included if they stopped receiving fingolimod between January 2014 and December 2015. Five patients were identified who experienced rebound after ceasing fingolimod treatment.EXPOSURESEach patient received treatment with oral fingolimod for various durations.MAIN OUTCOMES AND MEASURESOccurrence of rebound after ceasing fingolimod treatment.RESULTSThe mean (SD) age of the 5 female patients presented in this case series was 35.2 (6.4) years. Of the 46 patients that stopped fingolimod treatment within the 2-year period, 5 (10.9%) experienced severe relapse 4 to 16 weeks after ceasing fingolimod treatment. Despite varying prior severity of relapsing-remitting course, all participants experienced unexpectedly severe clinical relapses accompanied by drastic increases in new or enhancing lesions seen on magnetic resonance imaging evidenced by a median (range) increase of 9 (0->30) new gadolinium-enhancing lesions and a median (range) of 9 (0->30) new T2 lesions. New lesion development persisted for 3 to 6 months despite treatment with corticosteroids (n = 3) and initiation of B-cell depleting therapy (n = 2). In addition, 11 patients were identified through literature review reported as having severe relapses consistent with a rebound syndrome and similar features to our 5 cases.CONCLUSIONS AND RELEVANCEThese cases provide evidence for a fingolimod rebound syndrome at a clinically relevant frequency, highlighting the need to determine the best methods for sequencing or discontinuing MS therapies. A large prospective registry or population-based study would be helpful to confirm this rebound phenomenon and to determine contributing factors, including immune biomarkers, that increase risk for this syndrome. |
| Author | Hatcher, Stacy Ellen Waubant, Emmanuelle Graves, Jennifer S Crabtree-Hartman, Elizabeth Nourbakhsh, Bardia |
| Author_xml | – sequence: 1 givenname: Stacy Ellen surname: Hatcher fullname: Hatcher, Stacy Ellen organization: Department of Neurology, University of California, San Francisco – sequence: 2 givenname: Emmanuelle surname: Waubant fullname: Waubant, Emmanuelle organization: Department of Neurology, University of California, San Francisco – sequence: 3 givenname: Bardia surname: Nourbakhsh fullname: Nourbakhsh, Bardia organization: Department of Neurology, University of California, San Francisco – sequence: 4 givenname: Elizabeth surname: Crabtree-Hartman fullname: Crabtree-Hartman, Elizabeth organization: Department of Neurology, University of California, San Francisco – sequence: 5 givenname: Jennifer S surname: Graves fullname: Graves, Jennifer S organization: Department of Neurology, University of California, San Francisco |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27135594$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1kMFLwzAchYMobs79ByI5eulM0qRJjmM4FRTFTbwIJW1_0Yw0mU172H9vwfku7_Lx8XgX6DTEAAhdUbKghNDbnWlNgKGLfsEILRZEseIETRktVFZQISdontKOjFGE8JyfowmTNBdC8yn6fIMqDqHBm0NoutgCdgG_mt5B6BP-cP03fh587_Ye8Kb20MXkEl7aHjq8gpRGMgYcLV678BW9a2ODtx2Yvh0Fl-jMGp9gfuwZel_fbVcP2dPL_eNq-ZQZTkSf2ZzXoJtKUFnpcbEARQmXWjbaMmKJtUpxqOvG2FpXhVGUVsKKnHJQ2hSazdDNn3ffxZ8BUl-2LtXg_fhLHFJJFcmlFlKyEb0-okPVQlPuO9ea7lD-P8J-AaAVZsY |
| CitedBy_id | crossref_primary_10_1007_s40120_021_00320_w crossref_primary_10_3390_ijms20235985 crossref_primary_10_1177_1352458518763095 crossref_primary_10_1212_NXI_0000000000000377 crossref_primary_10_1055_a_2496_5294 crossref_primary_10_3390_children6060073 crossref_primary_10_1016_j_neurol_2023_03_028 crossref_primary_10_1212_NXI_0000000000001183 crossref_primary_10_1177_1352458520937644 crossref_primary_10_3389_fimmu_2019_01564 crossref_primary_10_1016_j_msard_2022_103805 crossref_primary_10_1080_17425255_2022_2138330 crossref_primary_10_1177_1756286419846818 crossref_primary_10_1177_1352458520929628 crossref_primary_10_1007_s00415_021_10556_z crossref_primary_10_1007_s40278_017_33427_6 crossref_primary_10_1111_cen3_12477 crossref_primary_10_1016_j_jns_2020_117156 crossref_primary_10_1177_13524585251342727 crossref_primary_10_3389_fneur_2018_00782 crossref_primary_10_1016_j_jns_2018_06_001 crossref_primary_10_1136_jnnp_2022_329607 crossref_primary_10_3390_cells10113177 crossref_primary_10_1080_14737175_2025_2508777 crossref_primary_10_1007_s00415_025_13283_x crossref_primary_10_1017_cjn_2018_17 crossref_primary_10_1007_s11910_023_01306_x crossref_primary_10_3389_fimmu_2023_1115120 crossref_primary_10_1155_2018_5190794 crossref_primary_10_3389_fimmu_2018_02669 crossref_primary_10_1016_j_msard_2018_08_006 crossref_primary_10_1111_cns_12992 crossref_primary_10_2147_DDDT_S240861 crossref_primary_10_1016_j_msard_2017_05_003 crossref_primary_10_1016_j_msard_2018_02_031 crossref_primary_10_1093_brain_awae409 crossref_primary_10_1016_S1634_7072_24_49343_4 crossref_primary_10_1186_s12883_024_03793_y crossref_primary_10_1111_ane_12882 crossref_primary_10_3390_cells11132058 crossref_primary_10_1007_s00415_019_09272_6 crossref_primary_10_1080_14656566_2017_1372747 crossref_primary_10_1111_ene_13536 crossref_primary_10_3389_fneur_2022_824926 crossref_primary_10_1177_1352458517741191 crossref_primary_10_3390_biomedicines8070227 crossref_primary_10_1007_s00415_022_11341_2 crossref_primary_10_1016_j_msard_2022_104157 crossref_primary_10_1212_WNL_0000000000201029 crossref_primary_10_1136_jnnp_2022_330104 crossref_primary_10_1002_jcph_945 crossref_primary_10_1016_j_msard_2020_102727 crossref_primary_10_1177_17562864211006499 crossref_primary_10_1186_s12883_021_02058_2 crossref_primary_10_1016_j_msard_2018_09_017 crossref_primary_10_1016_j_neurol_2019_08_008 crossref_primary_10_1155_2016_1034912 crossref_primary_10_1212_NXI_0000000000000719 crossref_primary_10_1007_s00415_019_09450_6 crossref_primary_10_1177_13524585211049986 crossref_primary_10_1016_j_ejmech_2025_117508 crossref_primary_10_1016_j_msard_2023_105134 crossref_primary_10_1212_WNL_0000000000004354 crossref_primary_10_1177_17562864231162153 crossref_primary_10_3389_fmed_2025_1593933 crossref_primary_10_1007_s40120_022_00339_7 crossref_primary_10_1016_j_msard_2021_102981 crossref_primary_10_1016_j_msard_2021_103278 crossref_primary_10_1016_j_msard_2023_104564 crossref_primary_10_1177_13524585221111677 crossref_primary_10_1016_j_ncl_2018_09_007 crossref_primary_10_1007_s40120_024_00654_1 crossref_primary_10_1007_s40265_023_01942_0 crossref_primary_10_1007_s11940_024_00814_6 crossref_primary_10_1016_j_msard_2018_11_034 crossref_primary_10_1002_acn3_410 crossref_primary_10_1007_s00415_019_09424_8 crossref_primary_10_1007_s11055_018_0619_z crossref_primary_10_1212_CON_0000000000000738 crossref_primary_10_1111_ane_12864 crossref_primary_10_1177_1352458517751049 crossref_primary_10_1007_s40265_017_0814_1 crossref_primary_10_1177_1756286420936166 crossref_primary_10_1016_j_msard_2023_105100 crossref_primary_10_1177_13524585231200719 crossref_primary_10_1016_j_intimp_2023_111192 crossref_primary_10_1016_j_msard_2020_101938 crossref_primary_10_1016_j_msard_2021_103329 crossref_primary_10_1016_j_pharmthera_2017_11_001 crossref_primary_10_1016_j_jns_2017_07_014 crossref_primary_10_1038_s41582_019_0170_8 crossref_primary_10_1177_17562864221150312 crossref_primary_10_1007_s40266_019_00741_1 crossref_primary_10_36290_neu_2017_095 crossref_primary_10_1007_s00415_021_10956_1 crossref_primary_10_1016_j_nerep_2023_100175 crossref_primary_10_1016_j_msard_2019_101883 crossref_primary_10_1111_cen3_12397 crossref_primary_10_1007_s13311_017_0568_1 crossref_primary_10_1007_s40120_019_00160_9 crossref_primary_10_1016_j_msard_2019_101483 crossref_primary_10_1080_14740338_2024_2448826 crossref_primary_10_1007_s00415_021_10658_8 crossref_primary_10_1136_jnnp_2022_328797 crossref_primary_10_36290_neu_2016_064 crossref_primary_10_1177_1352458517731913 crossref_primary_10_1097_NRL_0000000000000154 crossref_primary_10_1016_j_msard_2020_101927 crossref_primary_10_1212_NXI_0000000000200110 crossref_primary_10_1212_NXI_0000000000200231 crossref_primary_10_1007_s15202_018_1900_2 crossref_primary_10_1177_1352458516682858 crossref_primary_10_1007_s40278_016_17554_2 crossref_primary_10_1016_j_jneuroim_2021_577599 crossref_primary_10_1111_cen3_12441 crossref_primary_10_1177_2055217318759692 crossref_primary_10_1002_acn3_52017 crossref_primary_10_1212_NXI_0000000000000874 crossref_primary_10_1002_advs_202300738 crossref_primary_10_7759_cureus_84587 crossref_primary_10_1177_13524585211005657 crossref_primary_10_1080_14737175_2023_2208347 crossref_primary_10_1016_j_neurol_2022_11_003 crossref_primary_10_1177_1756286419837809 crossref_primary_10_2217_nmt_2021_0005 crossref_primary_10_1016_j_msard_2020_102529 crossref_primary_10_1111_ene_13694 crossref_primary_10_7224_1537_2073_2023_050 crossref_primary_10_3389_fimmu_2018_01560 crossref_primary_10_1177_17562864241239117 crossref_primary_10_1080_14656566_2020_1774554 crossref_primary_10_1007_s00415_017_8594_9 crossref_primary_10_1177_2055217317730096 crossref_primary_10_1007_s11910_024_01355_w crossref_primary_10_1111_ene_70282 crossref_primary_10_1038_s41586_021_03227_6 crossref_primary_10_1007_s00415_021_10708_1 crossref_primary_10_1007_s40261_019_00804_6 crossref_primary_10_1016_j_msard_2018_07_001 crossref_primary_10_1016_j_neurot_2025_e00582 crossref_primary_10_1016_j_msard_2024_105757 crossref_primary_10_1016_j_msard_2019_101517 crossref_primary_10_1016_j_msard_2022_104066 crossref_primary_10_3390_cells9020482 crossref_primary_10_1111_cen3_12470 crossref_primary_10_1016_j_msard_2022_103812 crossref_primary_10_1007_s40263_022_00965_7 crossref_primary_10_1155_2019_7151685 crossref_primary_10_3390_jcm11206033 crossref_primary_10_1177_17562864241300047 crossref_primary_10_1111_cen3_12504 crossref_primary_10_1002_jmv_26279 crossref_primary_10_1016_j_mycmed_2024_101529 crossref_primary_10_1007_s13311_021_01106_6 crossref_primary_10_1186_s41983_021_00386_1 crossref_primary_10_1212_NXI_0000000000000508 crossref_primary_10_1038_nrneurol_2016_192 crossref_primary_10_1007_s10072_025_08098_7 crossref_primary_10_1016_j_msard_2021_103072 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7U8 7X8 C1K JXQ |
| DOI | 10.1001/jamaneurol.2016.0826 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed TOXLINE MEDLINE - Academic Environmental Sciences and Pollution Management Toxline |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) TOXLINE MEDLINE - Academic Environmental Sciences and Pollution Management |
| DatabaseTitleList | MEDLINE TOXLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2168-6157 |
| EndPage | 794 |
| ExternalDocumentID | 27135594 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GroupedDBID | 0R~ 4.4 53G AAGZG ABIVO ABJNI ACDNT ACGFS ACPRK ADBBV ADHGD AENEX AFRAH AHMBA ALMA_UNASSIGNED_HOLDINGS AMJDE ANMPU BRYMA C45 CGR CUY CVF EBD EBS ECM EIF EJD EMOBN EX3 H13 NPM OB2 OBH OHH OVD PQQKQ RAJ SV3 TEORI WOW 7U8 7X8 C1K JXQ |
| ID | FETCH-LOGICAL-a405t-f34ce9db517b96155e8104797d9f20f0ff884eccdafc9b6a811b5f5314e89a692 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 165 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000379420500010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| IngestDate | Thu Jul 10 22:43:09 EDT 2025 Thu Apr 03 07:08:30 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a405t-f34ce9db517b96155e8104797d9f20f0ff884eccdafc9b6a811b5f5314e89a692 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://jamanetwork.com/journals/jamaneurology/articlepdf/2516773/noi160024.pdf |
| PMID | 27135594 |
| PQID | 1803795772 |
| PQPubID | 23479 |
| PageCount | 5 |
| ParticipantIDs | proquest_miscellaneous_1803795772 pubmed_primary_27135594 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-07-01 |
| PublicationDateYYYYMMDD | 2016-07-01 |
| PublicationDate_xml | – month: 07 year: 2016 text: 2016-07-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | JAMA neurology |
| PublicationTitleAlternate | JAMA Neurol |
| PublicationYear | 2016 |
| References | 27669336 - JAMA Neurol. 2016 Nov 1;73(11):1375 27669463 - JAMA Neurol. 2016 Nov 1;73(11):1375-1376 27669526 - JAMA Neurol. 2016 Nov 1;73(11):1376 27136400 - JAMA Neurol. 2016 Jul 1;73(7):775-6 |
| References_xml | – reference: 27669463 - JAMA Neurol. 2016 Nov 1;73(11):1375-1376 – reference: 27136400 - JAMA Neurol. 2016 Jul 1;73(7):775-6 – reference: 27669526 - JAMA Neurol. 2016 Nov 1;73(11):1376 – reference: 27669336 - JAMA Neurol. 2016 Nov 1;73(11):1375 |
| SSID | ssj0000800434 |
| Score | 2.567908 |
| Snippet | The appropriate sequencing of agents with strong immune system effects has become increasingly important. Transitions require careful balance between safety... IMPORTANCEThe appropriate sequencing of agents with strong immune system effects has become increasingly important. Transitions require careful balance between... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 790 |
| SubjectTerms | Adult Female Fingolimod Hydrochloride - adverse effects Humans Immunosuppressive Agents - adverse effects Longitudinal Studies Magnetic Resonance Imaging Middle Aged Multiple Sclerosis - diagnostic imaging Multiple Sclerosis - drug therapy Multiple Sclerosis, Relapsing-Remitting - chemically induced Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging PubMed - statistics & numerical data Recurrence |
| Title | Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/27135594 https://www.proquest.com/docview/1803795772 |
| Volume | 73 |
| WOSCitedRecordID | wos000379420500010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvVvC62iSbZPckpVi8tBRasQehZB-DAUmqqf5-Z5NtPQmCl9yyhPlmdz52Jt9HyI1SBqzihmnJU8aRUDOlQ8uSTIQa61tkkqw2m0iHQzGdypG_cKv8WOXyTKwPalNqd0d-F4hOlMoYyeD9_J051yjXXfUWGuukFSGVcVmdTsXqjsWxIR7x1R9zjdhQLRTpug5BcosFMPmdW9Y1pr_736_bIzueXdJukw77ZM0WB2Rr4Pvnh-QFo-l8lOjYCxXQvKCjRlq1os_54pUO_IQhHeMKWELzinadjzjtObMUByMtgfax4pVviLOhk-Wo-hF56j9Meo_M-yuwDGnagkHEtZVGxUGqpOtPWuGEG2RqJIQd6AAIwRFik4GWCtELAhUDblpuhcwSGR6TjaIs7CmhOozDTCO7yCLFIdBCAODiAEkM0kSmTa6XcZth_rqmBOJQflazn8i1yUkT_Nm8EdqYhc4_MJb87A9vn5Nth2gzSXtBWoC7116STf21yKuPqzox8DkcDb4BMBbHVA |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rebound+Syndrome+in+Patients+With+Multiple+Sclerosis+After+Cessation+of+Fingolimod+Treatment&rft.jtitle=JAMA+neurology&rft.au=Hatcher%2C+Stacy+Ellen&rft.au=Waubant%2C+Emmanuelle&rft.au=Nourbakhsh%2C+Bardia&rft.au=Crabtree-Hartman%2C+Elizabeth&rft.date=2016-07-01&rft.eissn=2168-6157&rft.volume=73&rft.issue=7&rft.spage=790&rft_id=info:doi/10.1001%2Fjamaneurol.2016.0826&rft_id=info%3Apmid%2F27135594&rft_id=info%3Apmid%2F27135594&rft.externalDocID=27135594 |